Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Arvinas

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Pfizer agrees pricing and distribution deal with US government

The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

- PMLiVE

Lilly reports survival benefit with Verzenio in high-risk early breast cancer

The findings are based on Lilly’s phase 3 monarchE trial

- PMLiVE

Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links